D.E. Shaw & Co
CLDX icon

D.E. Shaw & Co’s Celldex Therapeutics CLDX Stock Holding History

D.E. Shaw & Co’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,380
Closed -$366K – 4225
2014
Q1 		$366K Sell
1,380
-167
-11% -$63.9K ﹤0.01% 3812
2013
Q4 		$562K Hold
1,547
– – ﹤0.01% 3646
2013
Q3 		$822K Buy
+1,547
New +$530K ﹤0.01% 3215

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

D.E. Shaw & Co's CLDX Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Celldex Therapeutics (CLDX) stake by 61% in Q1 2026, selling an estimated $2.28M and leaving 52,860 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #3048.

D.E. Shaw & Co first reported a position in CLDX in Q2 2013 and has held it in 44 quarters since. The position peaked at $31.3M in Q2 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • D.E. Shaw & Co held 52,860 shares of Celldex Therapeutics worth $1.68M as of Q1 2026.
  • D.E. Shaw & Co sold 83,464 Celldex Therapeutics shares in Q1 2026, an estimated $2.28M.
  • Celldex Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3048 holding.
  • D.E. Shaw & Co first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 44 quarters since.
  • D.E. Shaw & Co's Celldex Therapeutics position peaked at $31.3M in Q2 2024.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.